Earnings Analyses

Reported results, market expectations and a look at the next quarter.

Verdicts Across Listed Reports7 Analyses

BUY4

HOLD3

SELL0

Wednesday, August 5Pre-Market

Eli Lilly and Co

LLY · Q2 2026Healthcare · Pharmaceuticals

85/ 100

VerdictBUY

Lilly grew revenue 48% year over year to $22.97 billion and lifted its full-year revenue outlook by roughly $3 billion. The stock rose 4.9%, but enthusiasm stayed measured. The real debate is not growth: it is how long the price erosion and the oral pill's slow start will last.

Revenue Growth (YoY): + 48%
EPS Surprise: + 27%
Post-Earnings Reaction: + 4.9%

In 30 SecondsRevenue rose 48% year over year to $22.97B; adjusted EPS of $8.38 beat the estimate by 27%.

Analyzed This Week

22 AnalysesShow All

AXPQ3 2026HOLD · 62

Latest Earnings Analyses

All This Week Industrials Consumer Staples Media & Telecom Financials Technology Utilities Semiconductors Consumer Health Care Energy Materials

By Date By Score By Reaction

Reaction strips share one scale: ±10%

LLY
Eli Lilly and Co · Q2 2026
85
VerdictBUY
First Reaction▲ 4.9%
Revenue YoY
▲ 48%
EPS vs Estimate
+ 27.0%
Aug 5 · Pre-Market
AMGN
Amgen Inc · Q2 2026
78
VerdictBUY
First Reaction▲ 4.6%
Revenue YoY
▲ 10%
EPS vs Estimate
+ 12.0%
Aug 4 · After Close
TMO
Thermo Fisher Scientific · Q3 2026
62
VerdictHOLD
First Reaction▲ 1.0%
Revenue YoY
▲ 9%
EPS vs Estimate
+ 4.4%
Oct 21 · Pre-Market
MRK
Merck & Co · Q2 2026
56
VerdictHOLD
First Reaction▲ 0.2%
Revenue YoY
▲ 5%
EPS vs Estimate
+ 50.0%
Aug 4 · Pre-Market
UNH
UnitedHealth Group · Q3 2026
73
VerdictBUY
First Reaction▼ 0.2%
Revenue YoY
▼ 0%
EPS vs Estimate
+ 13.3%
Oct 13 · Pre-Market
ABBV
AbbVie Inc · Q2 FY2026
74
VerdictBUY
First Reaction▼ 2.5%
Revenue YoY
▲ 10%
EPS vs Estimate
+ 0.3%
Jul 31 · Pre-Market
JNJ
Johnson & Johnson · Q3 2026
56
VerdictHOLD
First Reaction▼ 5.7%
Revenue YoY
▲ 6%
EPS vs Estimate
+ 2.4%
Oct 13 · Pre-Market